J&J's Reminyl Adds Mortality Precaution For Mild Cognitive Impairment
This article was originally published in The Pink Sheet Daily
Executive Summary
The Precautions section of labeling cites two Reminyl studies in patients with mild cognitive impairment in which the treatment-group mortality rate exceeded that of the placebo arm. J&J issues a "Dear Health Care Professional" letter alerting prescribers to the revised labeling.